Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder
Status unconfirmed
Conditions studied: Fetal Alcohol Spectrum Disorders
In brief
The objective of the study is to validate epigenetic changes as biomarkers in a prospective sampling of newborn blood samples collected at birth (umbilical cord blood) and during routine screening (heel stick blood) in newborns concurrently tested for alcohol exposure levels by PEth blood spot testing.
Key facts
- Study ID
- NCT03494738
- Run by
- CAMC Health System
- People needed
- 600
- Starts
- 2018-04-12
- Expected to finish
- 2022-12-31
- Last updated by the study team
- 2022-09-02
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Women aged ≥ 18 years and currently pregnant at time of enrollment
- Women who plan to and then deliver their infants at CAMC Women and Children's Hospital
You may not qualify if…
- Women aged < 18 years
- Women not pregnant
- Women who do not plan to deliver or did not end up delivering their infants at CAMC Women and Children's Hospital
- Infants:
- Inclusion criteria
- Birth mother was consented prior to delivery
- Live birth at CAMC Women and Children's Hospital
- Exclusion criteria
- Birth mother was NOT consented prior to delivery
- Stillborn
Where it is running
- CAMC - Women and Children's Hospital — Charleston, West Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.